Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics (CCCC)
NASDAQ:CCCC
Total Valuation
C4 Therapeutics has a market cap or net worth of $203.55M. The enterprise value is -$50.09M.
Market Cap$203.55M
Enterprise Value-$50.09M
Share Statistics
C4 Therapeutics has 71,170,815 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding71,170,815
Owned by Insiders2.43%
Owned by Institutions45.78%
Financial Efficiency
C4 Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -38.61%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-38.61%
Return on Capital Employed (ROCE)-0.39
Revenue Per Employee323.49K
Profits Per Employee-957.42K
Employee Count110
Asset Turnover0.10
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of C4 Therapeutics is ―. C4 Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.16
Price to FCF―
Price to Operating Cash Flow-1.89
PEG Ratio―
Income Statement
In the last 12 months, C4 Therapeutics had revenue of 35.58M and earned -105.32M in profits. Earnings per share was -1.52.
Revenue35.58M
Gross Profit35.58M
Operating Income-119.61M
Pretax Income-105.19M
Net Income-105.32M
EBITDA-103.37M
Earnings Per Share (EPS)-1.52
Cash Flow
In the last 12 months, operating cash flow was -87.41M and capital expenditures -168.00K, giving a free cash flow of -87.58M billion.
Operating Cash Flow-87.41M
Free Cash Flow-87.58M
Free Cash Flow per Share-1.23
Dividends & Yields
C4 Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta3.45
52-Week Price Change-54.38%
50-Day Moving Average1.98
200-Day Moving Average2.71
Relative Strength Index (RSI)64.34
Average Volume (3m)1.86M
Important Dates
C4 Therapeutics upcoming earnings date is Oct 30, 2025, After Close (Confirmed).
Last Earnings DateAug 7, 2025
Next Earnings DateOct 30, 2025
Ex-Dividend Date―
Financial Position
C4 Therapeutics as a current ratio of 5.71, with Debt / Equity ratio of 36.15%
Current Ratio5.71
Quick Ratio5.71
Debt to Market Cap0.00
Net Debt to EBITDA-0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, C4 Therapeutics has paid 131.00K in taxes.
Income Tax131.00K
Effective Tax Rate>-0.01
Enterprise Valuation
C4 Therapeutics EV to EBITDA ratio is -2.52, with an EV/FCF ratio of -3.98.
EV to Sales7.31
EV to EBITDA-2.52
EV to Free Cash Flow-3.98
EV to Operating Cash Flow-3.99
Balance Sheet
C4 Therapeutics has $214.55M in cash and marketable securities with $62.92M in debt, giving a net cash position of -$151.63M billion.
Cash & Marketable Securities$214.55M
Total Debt$62.92M
Net Cash-$151.63M
Net Cash Per Share-$2.13
Tangible Book Value Per Share$3.11
Margins
Gross margin is 86.24%, with operating margin of -336.15%, and net profit margin of -295.96%.
Gross Margin86.24%
Operating Margin-336.15%
Pretax Margin-295.60%
Net Profit Margin-295.96%
EBITDA Margin-290.49%
EBIT Margin-295.60%
Analyst Forecast
The average price target for C4 Therapeutics is $4.75, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.75
Price Target Upside72.10% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast16.55%
EPS Growth Forecast16.73%